Abstract: A gateway apparatus and a method for dynamically applying API settings are disclosed. The gateway apparatus includes a sub-processing unit processing an API (application programming interface) request of a client terminal based on API settings through a plurality of sub-threads, a setting unit comprising a first rule table and a second rule table to store a set value for processing the API request, and a reference flag, and a main processing unit updating new API settings in a rule table other than the rule table corresponding to a reference value of the reference flag through a main thread when receiving the new API settings, and setting the reference value of the reference flag to a reference value corresponding to the updated rule table when the update is completed.

Abstract: The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11?-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11?-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11?-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11?-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11?-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11?-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract: 2-pyridyl substituted imidazoles of the formula (I) as shown in claim 1, are provided, which are useful in the treatment of diseases mediated by ALK5 or ALK4 inhibitors or both.

Abstract: The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

Abstract: 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 inhibitors or both.

Abstract: The present invention relates to novel quinazoline derivatives effective in lowering blood glucose level and body weight, and a medicine for treatment and/or prevention of diabetes and/or obesity, which comprises the compound as an active ingredient.

Abstract: A stacked DRAM cell capacitor having HSG silicon only on a top portion of a storage node, not on a bottom portion thereof. The storage node has a double layer structure including a bottom layer and a top layer. The bottom layer is made of a conductive material that suppresses the growth of HSG seeds. Accordingly, electrical bridges between adjacent storage nodes, particularly at a bottom portion, can be prevented.

Abstract: A stacked DRAM cell capacitor having HSG silicon only on a top portion of a storage node, not on a bottom portion thereof. The storage node has a double layer structure including a bottom layer and a top layer. The bottom layer is made of a conductive material that suppresses the growth of HSG seeds. Accordingly, electrical bridges between adjacent storage nodes, particularly at a bottom portion, can be prevented.

Abstract: A stacked DRAM cell capacitor having HSG silicon only on a top portion of a storage node, not on a bottom portion thereof. The storage node has a double layer structure including a bottom layer and a top layer. The bottom layer is made of a conductive material that suppresses the growth of HSG seeds. Accordingly, electrical bridges between adjacent storage nodes, particularly at a bottom portion, can be prevented.